Dong-Wan Kim
Seoul National University
H-index: 112
Asia-South Korea
Top articles of Dong-Wan Kim
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201 | Lung Cancer | Byoung Chul Cho Ji-Youn Han Ki Hyeong Lee Yun-Gyoo Lee Dong-Wan Kim | 2024/2/20 |
Characterization of the phylogenetic relationships in bilateral breast angiosarcoma | Cancer Research | Minju Kim Jeonghwan Youk Soyeon Kim Miso Kim Bhumsuk Keam | 2024/3/22 |
Pralsetinib in patients with RET fusion–positive non-small-cell lung cancer: A plain language summary of the ARROW study | Frank Griesinger Giuseppe Curigliano Vivek Subbiah Christina S Baik Daniel SW Tan | 2024/2/1 | |
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC | Annals of Oncology | HA Yu C Baik D-W Kim ML Johnson H Hayashi | 2024/2/17 |
The synergistic potential of PARP inhibitors and irinotecan in small cell lung cancer | Cancer Research | Songji Oh Miso Kim Soyeon Kim Bhumsuk Keam Jeonghwan Youk | 2024/3/22 |
Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in NSCLC | Cancer Research and Treatment | Hanbaek Yi Jeonghwan Youk Yoojoo Lim Hanseong Roh Dongsoo Roh | 2024/1/8 |
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial | Nature Medicine | Benjamin Besse Elvire Pons-Tostivint Keunchil Park Sylvia Hartl Patrick M Forde | 2024/2/13 |
Synergistic effects of EZH1/2 dual inhibition and cisplatin on lung cancer cell lines with loss of SMARCA4 and SMARCA2 | Cancer Research | Jeongjae Lee Bhumsuk Keam Soyeon Kim Jeonghwan Youk Miso Kim | 2024/3/22 |
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions | Dong-Wan Kim Alison M Schram Antoine Hollebecque Kazumi Nishino Teresa Macarulla | 2024/1 | |
Molecular and Treatment Characteristics of SMARCB1 or SMARCA4-Deficient Undifferentiated Tumor: Retrospective Case Series | Cancer Research and Treatment | Hyeon Gyu Kang Jiwon Koh Tae Min Kim Doo Hee Han Tae-Bin Won | 2024/2/13 |
11P Patritumab deruxtecan (HER3-DXd) in previously treated patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC: Updated safety results from HERTHENA-Lung01 | ESMO Open | H Hayashi Y Goto HA Yu PA Jänne JC-H Yang | 2024/3/1 |
Long-term benefit of sotorasib in patients with KRAS G12C–mutated non–small-cell lung cancer: plain language summary | Grace K Dy Ramaswamy Govindan Vamsidhar Velcheti Gerald S Falchook Antoine Italiano | 2024/1 | |
Benchmark thermodynamic contributors to the growth and decay of the regional extreme surface temperature | Journal of Climate | Dong Wan Kim Sukyoung Lee Joseph P Clark Steven B Feldstein | 2024/2/9 |
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations | Lung Cancer | David S Hong Federico Cappuzzo Byoung Chul Cho Afshin Dowlati Maen Hussein | 2024/2/22 |
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset | Journal of Clinical Oncology | Byoung Chul Cho Myung-Ju Ahn Jin Hyoung Kang Ross A Soo Thanyanan Reungwetwattana | 2023/9/10 |
Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study | Lung Cancer | Dong-Wan Kim Byoung Chul Cho Krishna Pachipala Sang-We Kim Chih-Liang Wang | 2024/4/1 |
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer | Clinical Pharmacokinetics | Joseph Chen Alessandra Bearz Dong-Wan Kim Hirva Mamdani Jessica Bauman | 2024/2 |
P2. 04-02 AVANZAR: Phase III Study of Datopotamab Deruxtecan (Dato-DXd)+ Durvalumab+ Carboplatin as 1L Treatment of Advanced/mNSCLC | Journal of Thoracic Oncology | C Aggarwal P Cheema O Arrieta L Bonanno H Borghaei | 2023/11/1 |
NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant … | Florian Guisier Jaafar Bennouna Alexander I Spira Dong-Wan Kim Byoung Yong Shim | 2023/6/1 | |
Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistance | Journal of Cancer Research and Clinical Oncology | Jung Sun Kim Soyeon Kim Jaemoon Koh Miso Kim Bhumsuk Keam | 2023/6 |
